Farapulse and Medtronic expect pulsed field ablation (PFA) technology to eventually dominate the US atrial fibrillation ablation catheter market, but the companies are sponsoring very different US pivotal trials of their respective PFA systems.
PFA creates short, powerful electric pulses that precisely destroy cardiac myocyte cells with irreversible electroporation. Multiple companies are developing PFA systems because preclinical studies and early clinical trials suggest that PFA ablation is safer and easier to control ablation systems that heat or freeze tissue
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?